Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors

BACKGROUND: Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally ad...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Gastrointest Oncol
Main Authors: Saif, Muhammad Wasif, Parikh, Rohan, Ray, David, Kaye, James A., Kurosky, Samantha K., Thomas, Katharine, Ramirez, Robert A., Halfdanarson, Thorvardur R., Beveridge, Thomas J. R., Mirakhur, Beloo, Nagar, Saurabh P., Soares, Heloisa P.
Format: Artigo
Sprog:Inglês
Udgivet: AME Publishing Company 2019
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657323/
https://ncbi.nlm.nih.gov/pubmed/31392048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.03.11
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker